A Phase I/II, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Tor Kinase Inhibitor (AZD8055) in Asian Patients With Advanced Stage Hepatocellular Carcinoma (HCC) and With Mild or Moderate Hepatic Impairment.

Trial Profile

A Phase I/II, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Tor Kinase Inhibitor (AZD8055) in Asian Patients With Advanced Stage Hepatocellular Carcinoma (HCC) and With Mild or Moderate Hepatic Impairment.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Jul 2012

At a glance

  • Drugs AZD 8055 (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions; Biomarker; Pharmacokinetics
  • Most Recent Events

    • 30 Jan 2012 Actual patient number is 26 according to ClinicalTrials.gov.
    • 30 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Jan 2012 Planned end date changed from 1 Feb 2012 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top